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ABSTRACT:  
 
Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between 
antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP 
pharmacodynamic mechanisms are poorly understood. AED-SGAP combinations are used for treating co-
morbid illnesses or increasing efficacy, particularly in bipolar disorder.  
 
Areas covered: This article provides a comprehensive review of the interactions between antiepileptics 
and second-generation antipsychotics. The authors cover pharmacokinetic AED-SGAP DI studies, the 
newest drug pharmacokinetics in addition to the the limited pharmacodynamic DI studies. 
 
 Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the 
inductive properties of carbamazepine, phenytoin, phenobarbital and primidone.   More pharmacokinetic 
studies are needed to establish the clinical relevance of combining: i) AED strong inducers with 
amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, 
asenapine, clozapine and olanzapine; and iii) high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate 
(≥ 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two 
pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in 
bipolar disorder, and ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. 
Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and 
swallowing disturbances. A few AED-SGAP combinations may increase risk for osteoporosis or nausea. 
Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leucopenia 
and heat stroke.  Collaboration from all interested parties including: i) drug agencies and pharmaceutical 
companies; ii) clinicians using these combinations; iii) researchers with expertise in meta-analyses, 
pharmacoepidemiology, and DI pharmacology; and iv) grant agencies) is needed to progress in this area. 
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Keywords: Amisulpride; anticonvulsants; antipsychotics; aripiprazole; asenapine; bipolar disorder; 
carbamazepine; clozapine; eslicarbazepine; drug interactions; ethosuximide; felbamate; gabapentin; 
iloperidone; lacosamide; lamotrigine; levetiracetam; lurasidone; olanzapine; oxcarbazepine; paliperidone; 
pharmacokinetics;  phenobarbital; phenytoin; pregabalin; primidone; quetiapine; retigabine; risperidone; 
rufinamide; stiripentol; tiagabine; topiramate; valproate;  vigabatrin; ziprasidone; zonisamide. 
 
Highlights box 
-Drug-drug interactions (DIs) between antiepileptics (AEDs) and second-generation antipsychotics 
(SGAPs) are frequently clinically relevant.  
-More pharmacokinetic DI studies are needed for: i) AED strong inducers with amisulpride, asenapine, 
iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and 
olanzapine; and iii) high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400 mg/day) with 
SGAPs dependent on CYP3A4 (aripiprazole, lurasidone, quetiapine and risperidone) or UGTs (asenapine 
and olanzapine) for their metabolism.  
-The pharmacodynamic science of AED-SGAP DIs is in its infancy. 
-Possible beneficial pharmacodynamic DIs are: i) valproate-SGAP combinations for bipolar disorder, and 
ii) combining topiramate or zonisamide with SGAPs to decrease weight gain.  
-Pharmacodynamic AED-SGAP DIs may increase risk for sedation, weight gain, swallowing 
disturbances, osteoporosis, nausea, pancreatitis, agranulocytosis/leucopenia and heat stroke.   
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1. Introduction 
Antiepileptics (AED) can be divided into first-generation AEDs (FGAEDs) and second-generation 
AEDs (SGAEDs). Their clinically relevant drug interactions (DIs) with antipsychotics (APs) are the focus 
of this review. APs can similarly be divided into first-generation APs (FGAPs) and second-generation 
antipsychotics APs (SGAPs). Prior DI reviews [1, 2] included a particularly comprehensive review [2], 
but since its publication [2], no studies of clinically relevant DIs between FGAPs and AEDs have 
appeared. This article provides an updated review of clinically relevant DIs between AEDs and SGAPs. 
The introduction provides a brief description of AEDs, SGAPs, their pharmacokinetics, their 
pharmacodynamics and co-prescription. 
1.1. AEDs 
AED drugs are widely used not only for the treatment of epilepsy, but also for the management of 
a variety of non-epileptic neurological conditions and psychiatric disorders [3].  The FGAEDs include 
carbamazepine, ethosuximide, phenytoin, phenobarbital, primidone and valproate (Table 1). The 
SGAEDs include eslicarbazepine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, 
oxcarbazepine, pregabalin, retigabine, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and 
zonisamide (Table 1). Some SGAEDs (eslicarbazepine, retigabine, stiripentol, and vigabatrin) are not 
marketed in the US.  When compared with FGAEDs, most SGAEDs except for felbamate are 
characterized by better safety profiles with fewer adverse drug reactions (ADRs) and less DI risk than 
FGAEDs. The only FGAED that continues to be a first-line choice AED may be valproate, but its 
teratogenicity risk is contributing to its decreased use in females of fertile age.  There are no definitive 
studies comparing the efficacy of all FGAEDs and the most important SGAEDs in the same study, but in 
the developed countries SGAEDs, particularly lamotrigine, levetiracetam, and oxcarbazepine, have 
partially substituted for FGAEDs due to their better safety profiles [4,5].  
1.2. SGAPs 
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In recent years, SGAPs (amisulpride, aripiprazole, asenapine, clozapine, iloperidone, lurasidone, 
olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) (Table 2) have progressively replaced 
FGAPs in the developed countries due to better safety profiles for reversible extrapyramidal symptoms 
and tardive dyskinesia, and better marketing. SGAPs are widely used not only for schizophrenia and 
bipolar disorder, but for adjuvant treatment of major depressive disorder, psychosis and behavioral 
disorders in dementia, psychosis associated with Parkinson's disease, resistant obsessive-compulsive 
disorder, aggressive behavior and irritability in autism spectrum disorders [6].   
1.3. Pharmacokinetics 
There are two basic types of DIs, pharmacokinetic and pharmacodynamic DIs. Pharmacokinetic 
DIs can be established and quantified by the study of changes in plasma drug concentrations, usually 
called therapeutic drug monitoring (TDM), and can occur at absorption, distribution, metabolism or 
excretion of a drug and/or its metabolite(s). The most important pharmacokinetic DIs are the metabolic 
DIs. This subsection in pharmacokinetics focuses on the metabolism of AEDs and SGAPs and the clinical 
consequences of pharmacokinetic DIs. Figure 1 discusses the possibility of non-metabolic 
pharmacokinetic DIs based on the P-glycoprotein (P-gp) or protein binding [7].   
1.3.1. Metabolism 
The cytochrome P450 (CYP) isoenzymes are the most important oxidative enzymes; the uridine 
diphosphate glucuronosyltransferases (UGTs) are the most important conjugation enzymes. CYP 
substrates, inhibitors and inducers are well established while those for UGTs are less known.  
1.3.1.1. AED metabolism. FGAEDs are extensively metabolized in the liver by CYPs and UGTs (Table 
1). By contrast [8], many SGAPs have less propensity for pharmacokinetic DIs because they are not 
metabolized at all (gabapentin, pregabalin and vigabatrin) and are renally cleared, or undergo minimal 
hepatic biotransformation (levetiracetam and rufinamide) (Table 1). Four FGAEDs, namely 
carbamazepine, phenytoin, phenobarbital and primidone, induce the activity of multiple enzymes 
including CYPs, UGTs and epoxide hydrolase (Table 3) [9]. Once steady state is present, inducers need a 
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few weeks, usually 2-4 weeks, to reach maximum effects and to disappear. Thus, sometimes it takes up to 
one month to see the whole effect of adding or discontinuing an inducer. Among FGAEDs, valproate is a 
broad-spectrum inhibitor of various drug-metabolizing enzymes including CYP2C9 and UGTs. Some of 
the newer AEDs may at times act as enzyme inhibitors. Eslicarbazepine, felbamate, oxcarbazepine and 
topiramate are weak inhibitors of CYP2C19, while stiripentol is a potent inhibitor of CYP1A2, CYP2C19, 
CYP2D6 and CYP3A4. Eslicarbazepine, felbamate, oxcarbazepine (particularly at dosages ≥ 1500 
mg/day) [10], rufinamide and topiramate (particularly at dosages ≥ 400 mg day) [11] can induce the 
activity of CYP3A4 and possibly some UGTs. 
1.3.1.2. SGAP metabolism. With the exception of amisulpride and paliperidone, SGAPs are targets of 
metabolic DIs because they undergo extensive hepatic biotransformation via CYPs and UGTs, which are 
highly inducible and readily inhibited. SGAPs appear not to be clinically relevant inhibitors or inducers 
[12] (see competitive inhibition in footnote 2, Table 2).  
1.3.2. Clinical consequence of pharmacokinetic DIs 
Metabolic DIs change the concentration-dose (C/D) ratio that reflects how the drug is cleared from 
the body at steady state. For SGAPs, the C/D ratio can be represented by a line (linear kinetics). 
Complicating predictions, some AEDs do not follow linear kinetics (Table 1), thus their C/D ratios may 
change with different concentrations.  Inhibitors increase the C/D ratio (lower substrate doses provide the 
same concentration) while inducers decrease the C/D ratio (higher substrate doses are required to reach 
the same concentration). Pharmacokinetic DI studies can be used to estimate correction factors, which are 
>1 in inducers and <1 in inhibitors. A correction factor of 2 indicates that you need to double the dose for 
the same effect. A correction factor of 0.5 indicates that you need to halve the dose for the same effect. 
The further the correction factor is from 1, the more relevant the DI may be. The therapeutic window or 
index also determines the clinical relevance of correction factors. Failing to correct for the therapeutic 
window after adding or discontinuing inducers or inhibitors may have much greater clinical consequences 
in drugs with narrow therapeutic windows. 
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1.4. Pharmacodynamics 
Most articles reviewing DIs ignore pharmacodynamic mechanisms of AED and SGAP, which are 
poorly understood.  This subsection provides a very brief reference to the pharmacodynamics of AEDs 
and SGAPs; they are described more comprehensively in Figures 2 to 5 and their detailed footnotes. At 
the end of this section, a subsection comments on the types of pharmacodynamic DIs. 
1.4.1. AED pharmacodynamics 
Figure 2 summarizes the AED’s mechanism of action in epilepsy, bipolar disorder, anxiety, pain, 
migraine prophylaxis and weight loss [3, 13-19]. Figure 3 summarizes the AED’s mechanism of action 
associated with major safety issues [20-36].  
1.4.2. SGAP pharmacodynamics 
Figure 4 summarizes the SGAPs’ mechanism of action, explaining their efficacy in schizophrenia, 
other psychoses and other psychiatric disorders [6, 37-42]. Many AP ADRs are explained by their 
blockade of neurotransmitter receptors (Figure 5) [43-59].  
1.4.3. Pharmacological knowledge and pharmacodynamic DIs 
Pharmacodynamic DIs take place directly at the site of action of a drug or indirectly by interfering 
with another physiological mechanism. They result in a modification of the pharmacological action of a 
drug without any change in the plasma concentration and are more difficult to identify and measure than 
pharmacokinetic DIs. These DIs can be additive (i.e., equal to the sum of the effects of the individual 
drugs), synergistic (i.e., combined effects are greater than expected from the sum of individual effects) or 
antagonistic (i.e., combined effects are less than additive) [9]. They can be associated with positive effects 
(increased efficacy and/or safety) or negative effects (decreased efficacy and/or safety). 
1.5. Co-prescription of AEDs and SGAPs 
AEDs and SGAPs are often prescribed together because co-morbidities may occur: i) AEDs are 
usually administered for prolonged periods in people with epilepsy and SGAPs may be needed to treat the 
highly prevalent psychiatric disorders seen in people with epilepsy; ii) autism spectrum disorders are 
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associated with very high risk of epilepsy, frequently with poor prognosis, and some SGAPs have been 
approved in the US market for the treatment of irritability in children with these disorders (Figure 4); or 
iii) AEDs may be used to treat non-epileptic conditions (e.g., neuropathic pain and migraine) in patients 
taking SGAPs.  
In other cases clinicians co-prescribed them to decrease ADRs (AED medications may be used to 
treat seizures associated with some SGAPs, clozapine is particularly associated with dosage-related 
seizures) or increase efficacy: several AEDs (carbamazepine, lamotrigine, and valproate) and SGAPs are 
approved for bipolar disorder. Therefore, combinations of AEDs and SGAPs are increasingly used in the 
management of bipolar disorder. Other AEDs are being studied as potential mood stabilizers 
(oxcarbazepine and zonisamide). Other adjunctive therapies are less established as effective in the 
literature including: i) valproate or carbamazepine added to SGAPs in people with schizophrenia or 
schizoaffective disorder to better treat the psychosis or for the management of aggressive behaviors, and 
ii) lamotrigine added to clozapine for the management of treatment-resistant schizophrenia.  
 In summary, 1) AEDs and SGAPs are frequently co-prescribed, 2) they have clinically relevant 
DIs, and 3) there is no recent comprehensive review of this subject.  
2. DI studies and their clinical relevance 
This section provides a comprehensive review of DI studies including three sections that order 
compounds alphabetically: 1) the metabolic DI studies, starting with a review of the effects of each AED 
on each SGAP and then the effects of the SGAPs on the AEDs; 2) predictions of the metabolic DIs for 
new AEDs and SGAPs; and 3) a review of the limited studies on pharmacodynamic DIs. Articles for this 
review were obtained from a PubMed search with no time limit and through hand-searching of a number 
of recent journals and recent reviews. Searches were performed for each of the AEDs and SGAPs.  This 
search was beyond the articles previously found and listed in the authors’ published literature reviews [9, 
12] and DI studies.  
2.1. Pharmacokinetic DI studies 
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2.1.1. Carbamazepine 
Carbamazepine is a powerful inducer of several drug-metabolizing enzymes including CYPs, 
namely CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP3A4, as well as UGTs, such as 
UGT1A1, UGT2B7, UGT2B15.   
2.1.1.1. Carbamazepine on aripiprazole. Carbamazepine decreased the mean area under the curve (AUC) 
of aripiprazole and dehydro-aripiprazole serum concentrations by 71% and 69%, respectively, in a study 
of 30 mg/day of aripiprazole for 14 days and then 4-6 weeks of carbamazepine titrated to concentrations 
of 8-12 g/mL [60]. Similarly, a study of 18 schizophrenia patients treated with aripiprazole found 400 
mg/day of carbamazepine, administered for 1 week, caused a significant decrease in aripiprazole and 
dehydro-aripiprazole concentrations by 64% and 68%, respectively [61]. A routine TDM study indicated 
that carbamazepine lowered dose-adjusted concentrations of aripiprazole by 88% [62].  
2.1.1.2. Carbamazepine on clozapine. In a TDM clozapine study, patients on carbamazepine had a mean 
50% lower C/D ratio of clozapine than the monotherapy group [63]. In a comparison of the effects of 
carbamazepine and oxcarbazepine on clozapine serum concentrations in 12 patients, Tiihonen et al. found 
that the clozapine concentration was 47% lower with carbamazepine than with oxcarbazepine [64]. 
Carbamazepine’s inducing effect on CYP1A2- and CYP3A4-mediated clozapine metabolism probably 
explains these results. 
2.1.1.3. Carbamazepine on olanzapine. A DI study of 11 healthy volunteers assessed a single 10 mg 
olanzapine dose before and after administration of carbamazepine 400 mg/day for 18 days [65]. 
Carbamazepine resulted in a 46% increase in olanzapine clearance and in a 34% decrease in its AUC. In 
carbamazepine patients the median dose-normalized olanzapine concentrations were 36-71% lower than 
in those in monotherapy according to TDM studies [66-69]. Specifically, Linnet and Olesen evaluated the 
influence of carbamazepine on olanzapine glucuronidation in a TDM study [67]. Two median differences 
were significant between 16 carbamazepine patients and 31 in monotherapy: i) free olanzapine C/D ratio 
was 38% lower (3.6 nmol/l/mg versus 5.8 nmol/l/mg), and ii) glucuronidated fraction (79% versus 43%) 
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[67]. Carbamazepine lowered free olanzapine concentration by increasing glucuronidation metabolism. 
All of these studies clearly indicated that carbamazepine increases olanzapine metabolism by CYP1A2- 
and UGT-induction. 
2.1.1.4. Carbamazepine on paliperidone. CYP inhibitors or inducers were not expected to have a 
significant influence on paliperidone metabolism but the US package insert describes 400 mg/day of 
carbamazepine as decreasing the mean steady-state serum peak concentration (Cmax) and the AUC of 
paliperidone by approximately 37%, due to a 35% increase in the renal clearance of paliperidone. This is 
attributed to carbamazepine induction of the renal P-gp. 
2.1.1.5. Carbamazepine on quetiapine. Carbamazepine (600 mg/day) decreased quetiapine Cmax by 80% 
and AUC by 87% and increased oral clearance by a 7.5-fold increase in a pharmacokinetic study of 18 
psychiatric patients [70].  TDM studies [71-74] provided similar results. In particular, in a large routine 
TDM database, the mean quetiapine C/D ratio was 9 times lower (0.02 versus 0.18) and significantly 
lower (95% confidence intervals 0.02-0.03 versus 0.17-0.19, p < 0.001) for the 39 carbamazepine-treated 
patients versus the 1123 patients on quetiapine monotherapy [72]. The DI clinical implications were 
demonstrated in three patients taking carbamazepine 400-800 mg/day in which serum quetiapine 
concentrations could not be detected (<25 ng/mL) despite taking 700 mg/day [75]. These massive 
pharmacokinetic changes are explained by the potent inducing effect of carbamazepine on CYP3A4-
mediated quetiapine metabolism. 
2.1.1.6. Carbamazepine on risperidone. A case report first reported that serum risperidone active moiety 
(risperidone and its pharmacologically active metabolite 9-hydroxy-risperidone) doubled after 
carbamazepine discontinuation, leading to an ADR [76]. A subsequent study indicated that risperidone 
moiety was approximately 1.4 times lower in 11 carbamazepine patients versus 23 patients on risperidone 
alone [77]. In 5 patients assessed on and off carbamazepine co-medication, risperidone moiety was 1.5 
times lower on carbamazepine [77]; in 11 other patients it was 1.8 times lower [78].  The clinical 
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relevance of the increase in risperidone metabolism attributed to the carbamazepine CYP3A4-inducing 
effects was demonstrated by an acute psychotic exacerbation in a case report [79].  
2.1.1.7. Carbamazepine on ziprasidone. Carbamazepine (400 mg/day) lowered ziprasidone mean Cmax by 
27% and mean AUC0-12h by 36% in 19 healthy volunteers taking 40 mg/day of ziprasidone [80].  
Carbamazepine probably induced CYP3A4-mediated ziprasidone metabolism. 
2.1.1.8. SGAPs on carbamazepine. Two weeks after the addition of risperidone (1 mg/day) the mean 
steady-state carbamazepine concentrations mildly increased by 19% in 8 epileptic patients [81], probably 
due to competitive inhibition of CYP3A4. Adding quetiapine led to a pharmacokinetic DI and ADRs in 2 
patients [82], probably due to the competitive inhibition of CYP3A4. 
2.1.2. Lamotrigine 
 Lamotrigine does not appear to be a CYP inhibitor or inducer but is a weak UGT inducer [9].   
2.1.2.1. Lamotrigine on clozapine. A case report associated a clozapine ADR with a 3-fold increase in 
serum clozapine concentrations when lamotrigine was added [83]. However two studies (a randomized 
clinical trial [RCT] in 34 hospitalized treatment-resistant patients [84] and a pharmacokinetic study in 11 
patients stabilized on clozapine [85]) found no serum clozapine concentration changes during lamotrigine 
treatment up to 200 mg/day.  
2.1.2.2. Lamotrigine on olanzapine. Although UGT1A4 metabolizes both lamotrigine and olanzapine, two 
studies of healthy volunteers using low lamotrigine doses (50 and 200 mg/day) found no effects on 
olanzapine pharmacokinetics [86, 87]. A mild (15%) but significant increase in steady-state olanzapine 
serum concentration was found in 14 patients taking olanzapine (10-20 mg/day) after adding 100 mg/day 
of lamotrigine [85]. By using a mixed model, Botts et al. confirmed that lamotrigine behaved as an 
olanzapine inhibitor in smokers, increasing the C/D ratio by 35%, whereas the lamotrigine produced a 
mild non-significant decrease in olanzapine C/D ratio in nonsmokers [69]. 
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2.1.2.3. Lamotrigine on quetiapine. A large TDM study reported a slight (17%) and significant 17% 
decrease in quetiapine C/D ratio in 147 lamotrigine patients when 1123 were on quetiapine monotherapy 
[62]. 
2.1.2.4. Lamotrigine and risperidone. An ADR case report described a 5-6-fold elevation in risperidone 
levels after adding lamotrigine [88].  However, a study of 10 psychotic patients stabilized on risperidone 
(3-6 mg/day), demonstrated that up to 200 mg/day of lamotrigine had no influence on serum risperidone 
moiety [85].   
2.1.2.5. SGAPs on lamotrigine. There was no influence on lamotrigine levels in:  i) a TDM study (N=829) 
with clozapine, risperidone or olanzapine co-prescription [89], and ii) an aripiprazole study with 30 
mg/day in 18 bipolar patients [90].  
2.1.3. Phenobarbital/phenytoin 
Phenobarbital and phenytoin are considered powerful and promiscuous inducers of CYPs, 
(including CYP1A2, CYP2C, and CYP3A4) as well as UGTs.  
2.1.3.1. Phenobarbital/phenytoin on clozapine. Two patients had a psychotic exacerbation after adding 
phenytoin, which decreased clozapine levels by 65-85% [91]. Lane et al. described a patient with a 
remarkable elevation of clozapine levels 2 weeks after phenobarbital discontinuation [92].   Facciolà et al. 
found that serum clozapine concentrations were significantly lower in 7 phenobarbital-treated patients 
than in 15 monotherapy patients (232 ± 104 ng/ml versus 356 ± 13 ng/ml) and attributed this decrease to 
CYP1A2- and CYP3A4-induction [93].  
2.1.3.1. Phenytoin on quetiapine. Quetiapine clearance increased more than 5-fold from 80.3 ± 35.9 l/hr to 
440 ± 214 l/hr when comparing 10 patients on 750 mg/day after receiving phenytoin (300 mg/day) [94].  
2.1.4. Oxcarbazepine  
Oxcarbazepine is a keto-analog of carbamazepine. Unlike carbamazepine, this AED seems to be a 
modest CYP3A4 inducer [9]. As previously mentioned, carbamazepine was associated with lower 
clozapine levels in 12 patients when compared with oxcarbazepine [64]. Minimal and not significant 
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serum concentration modifications occurred after a 5-week treatment of oxcarbazepine (900-1200 
mg/day) in psychotic patients stabilized on risperidone (2-6 mg/day; n=12) or olanzapine (5-20 mg/day; 
n=13) [95].  
2.1.5. Topiramate  
Topiramate is a weak inhibitor of CYP2C19 and a weak inducer of CYP3A4 [9]. Adding up to 
200 mg/day of topiramate brought no serum concentration modifications for clozapine (250-500 mg/day, 
n=10), olanzapine (10-20 mg/day, n=12), risperidone (3-6 mg/day, n=9) or quetiapine (200-600 mg/day, 
n=7) [96]. It cannot be ruled out that higher topiramate doses may have an inductive effect in these 
SGAPs. 
2.1.6. Valproate 
Valproate has traditionally been considered a broad-spectrum metabolic enzyme inhibitor. It 
inhibits CYP2C9 competitively, CYP2C19 and CYP3A4 weakly and has no effects on CYP1A2, 
CYP2D6, and CYP2E1. It inhibits UGT enzymes (UGT1A4 and UGT2B7) [9]. A recent human 
hepatocyte study surprisingly demonstrated that valproate may induce some enzymes (CYP3A4 and P-gp 
gene expression) [97]. 
2.1.6.1. Valproate on aripiprazole. A decrease of 26% in the aripiprazole Cmax and of 24% in the 
aripiprazole AUC with minimal effects on the active metabolite of aripiprazole after valproate addition 
was found in an open study of 10 schizophrenia patients [98]. Similarly, in a TDM study aripiprazole C/D 
was 24% lower in 7 patients co-medicated with valproate than in 23 on aripiprazole monotherapy [62]. 
Aripiprazole is a CYP3A4 and P-gp substrate; thus valproate may mildly induce CYP3A4 and/or P-gp.  
Both can decrease intestine drug absorption.  
2.1.6.2.Valproate on clozapine. Early studies provided conflicting findings of increases and decreases of 
clozapine metabolism by valproate, which were unlikely to be clinically significant [reviewed by 99].  
The three best studies [100-102] suggested that valproate might inhibit clozapine conversion to 
norclozapine via CYP1A2 or CYP3A4.  In contrast, Finley and Warner found in four male patients that 
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clozapine concentrations decreased by 41% when valproate was administered [103].   By using a 
statistical mixed model that estimated the effect sizes of co-medications on clozapine levels after 
correcting for confounding variables, Diaz et al. found that valproate appeared to act as a clozapine 
inhibitor in non-smokers and as an inducer in smokers [99]. These findings may account for the 
inconsistent valproate results on clozapine metabolism. 
2.1.6.3. Valproate on olanzapine. As valproate and olanzapine share common metabolic pathways, a 
metabolic DI can occur. TDM studies found no valproate influence on olanzapine metabolism [69, 104].  
However, in four patients stabilized on olanzapine, valproate (1000-2700 mg/day) decreased olanzapine 
levels by 50% with a psychiatric deterioration in three of them [105].  Valproate co-administration (600-
2000 mg/day) was associated with a significant decrease in mean serum olanzapine concentrations from 
32.9 ± 9.7 ng/mL at baseline to 27.4 ± 9.8 ng/mL at week 2, and to 26.9 ± 9.2 ng/mL at week 4 in 18 
psychotic patients who had no relapses [106]. Serum olanzapine concentration drop varied from 2 to 4 
weeks and with valproate concentration and is likely to be explained by valproate induction on olanzapine 
metabolism by CYPs or UGT. These changes, although statistically significant, were small and 
presumably not clinically significant. However, as the valproate and olanzapine combination is 
increasingly used, further studies are necessary to elucidate the mechanisms (induction, competitive 
inhibition and/or protein binding displacement), severity and duration of this DI and to understand 
whether there are any circumstances (e.g., high or low olanzapine or valproate doses) in which this DI 
may acquire clinical relevance [107]. 
2.1.6.4. Valproate on quetiapine. Valproate studies on quetiapine metabolism provided inconsistent 
results. A 77% increase in quetiapine C/D, when compared to quetiapine monotherapy in 9 patients taking 
valproate, led Aichorn et al. to propose a CYP3A4-inhibition of quetiapine metabolism by valproate 
[108]. However no relevant changes in quetiapine metabolism were found in two TDM routine studies 
[72, 73] and in a formal pharmacokinetic study in 34 psychotic patients taking 300 mg/day of quetiapine 
and 1000 mg/day of divalproex [109].  
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2.1.6.5. Valproate on risperidone. No major changes in risperidone moiety were found in: i) a 
pharmacokinetic study comparing 23 patients on monotherapy versus 10 on valproate (1200-1500 
mg/day) [77], ii) its extension to 3 patients on/off valproate [77], and iii) another pharmacokinetic study 
of 22 bipolar patients taking valproate (1000 mg/day) in which half were randomized to placebo or 
risperidone up to 4 mg/day [110]. This is consistent with the absence of an inhibitory effect of valproate 
on CYP2D6 or CYP3A4, the major risperidone metabolic pathways. 
2.2. Predicting metabolic DIs for new compounds 
2.2.1. Other AEDs  
The DI information for other SGAEDs is limited. Eslicarbazepine and rufinamide (as well as the 
older felbamate) are mild CYP3A4-inducers. Rufinamide is also a possible UGT-inducer.  
Eslicarbazepine, felbamate and rufinamide have limited potential to induce SGAP metabolism. As 
CYP2C19 is not important in SGAP metabolism, the weak CYP2C19 inhibition by eslicarbazepine and 
felbamate is not likely to be relevant. Stiripentol is a potent inhibitor of CYP2C19, CYP1A2, CYP2D6, 
and CYP3A4 but is only used in Europe for the treatment of severe myoclonic epilepsy in infancy and is 
not likely to be co-prescribed with SGAPs. 
2.2.2. New SGAPs  
2.2.2.1. Asenapine. UGT1A4 and CYP1A2 metabolize asenapine. Valproate (1000 mg/day for 9 days) 
substantially reduced the formation of the N-glucuronide (AUC reduced 7.4-fold) and moderately reduced 
that of N-desmethyl-asenapine (AUC reduced 30%) but did not affect asenapine AUC in an open-label, 
randomized, 2-way crossover study in 24 healthy male volunteers receiving 5 mg of asenapine alone or a 
low valproate dose. The study’s authors, who were from the asenapine-marketing company, concluded 
that low-dose valproate, although almost completely inhibiting asenapine glucuronidation, did not affect 
asenapine clearance [111]. Asenapine’s package insert indicates that: 1) 800 mg/day of carbamazepine for 
15 days had small effects on asenapine AUC (16% decrease), and 2) no dosage adjustments are required. 
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Independent studies using multiple dosing are required to verify that the valproate and carbamazepine DIs 
with asenapine have no clinical relevance.  
2.2.2.2. Iloperidone. Iloperidone is metabolized by CYP2D6 and CYP3A4 [112]. CYP3A4 inhibitors 
have clinically relevant effects on iloperidone levels. There are no published studies of potent CYP3A4 
inducers which are expected to relevantly increase iloperidone metabolism.  
2.2.2.3. Lurasidone. Lurasidone is metabolized by CYP3A4 [113]. According to the US package insert, 
rifampin, a potent CYP3A4-inducer, decreased lurasidone AUC 5-fold.  There are no published studies of 
potent CYP3A4 inducers which are expected to dramatically increase lurasidone metabolism. It is 
possible that in high doses oxcarbazepine or topiramate may influence lurasidone levels. 
2.3. Limited studies on pharmacodynamic DIs 
This subsection classifies pharmacodynamic DIs as those increasing efficacy, increasing safety, 
decreasing efficacy, and decreasing safety. The most important are included in Table 5. 
2.3.1 Pharmacodynamic DIs increasing efficacy  
 Several SGAPs have been approved in the US for mania as adjuvant therapy to valproate (and 
lithium), including aripiprazole, asenapine, quetiapine, risperidone and olanzapine. In the RCTs, tested 
SGAPs were significantly more efficacious than adding placebo to valproate (or lithium). Thus, an 
additive (or synergistic) effect (see subsection 1.4.3.) between valproate and SGAPs is expected in mania 
(Table 5). In a review, Ketter described the response rate to valproate (and lithium) as increasing from 
21% to 42% when adding SGAPs [114], which suggests additive rather than synergistic effects.  
2.3.2. Pharmacodynamic DIs increasing safety  
Topiramate and zonisamide can decrease weight (Figure 2 and Table 5). Topiramate has been 
associated with reversing SGAP-induced weight gain in an open study [115]. 
2.3.2. Pharmacodynamic DIs decreasing efficacy  
 Figures 2-5 indicate that AEDs and SGAPs sometimes have opposite actions. All SGAPs, but 
particularly clozapine and to a lesser extent olanzapine and quetiapine (Figure 5), have potential to 
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decrease the seizure threshold and therefore contribute to seizures [53]. If a patient with epilepsy needs an 
SGAP, the potential for increased seizures needs to be considered. This is easily managed by monitoring 
AED treatment closely and considering increased AED doses, but in patients with not-well-controlled 
seizures, adding an SGAP that lowers the seizure threshold may produce a clinically relevant 
pharmacodynamic DI. 
 In epileptic patients, some AEDs (ethosuximide, levetiracetam, tiagabine, topiramate, vigabatrin 
and zonisamide) have rarely been associated with psychosis (usually a transient paranoid psychosis; 
Figure 3). As the pharmacodynamic mechanism is unknown, clinicians may want to remember this risk 
when considering co-prescribing them with SGAPs in patients whose psychosis is not well-controlled. In 
epileptic patients, some AEDs (particularly barbiturates, topiramate and vigabatrin, and less frequently 
felbamate, levetiracetam, tiagabine, and zonisamide) have been associated with depression (Figure 3).  
Clinicians may want to remember this risk when considering co-prescribing these AEDs with SGAPs in 
patients with bipolar disorder or treatment-resistant depression since they have the potential to antagonize 
the antidepressant SGAP properties. A Food and Drug Administration (FDA) meta-analysis of the 
placebo RCTs suggests that patients taking AEDs have an increased risk of suicidal thoughts and 
behaviors observed 1 week after taking the medication; the risk continues for at least 24 weeks which has 
led to a warning in the package inserts of all anticonvulsants [116]. Recently, reviews questioned the FDA 
warning in the prescription packages for all AEDs [117] and large pharmacoepidemiological studies 
suggested contradictory findings for AEDs in general [118,119].  In our opinion, 1) the FDA decision to 
include a warning about increased suicide risk in all antiepileptic prescribing information has increased 
awareness, but oversimplified a complex matter; 2) the risk of completed suicide in persons with suicidal 
ideation is probably low, while completed suicide risk increases 40-fold after a prior attempt [120]; and 3) 
other factors such as medical and psychiatric illnesses can partially explain the increased suicide risk in 
patients taking AEDs. 
2.3.3. Pharmacodynamic DIs decreasing safety.  
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There are multiple pharmacodynamic DIs that have potential to increase ADRs by additive or 
synergistic effects. These DIs are likely to be clinically relevant but have not been systematically studied. 
They can be divided into common, probably less common and rare, but potentially lethal, categories.  
Three common pharmacodynamic DIs are sedation, weight gain and swallowing disturbances 
(Table 5).  A recent well-controlled 12-month study indicated that the valproate-olanzapine combination 
was worse for metabolic syndrome than the valproate-risperidone combination [121]. Dysphagia is 
particularly frequent in patients with intellectual disabilities or dementia. Although it has not been studied 
additive or synergistic pharmacodynamic DI actions on swallowing disturbances are likely between AEDs 
and SGAPs. Table 5 emphasizes two probably uncommon pharmacodynamic DIs, nausea/vomiting and 
osteoporosis, which have never been studied, and includes three rare, but potentially lethal 
pharmacodynamic DIs: pancreatitis, agranulocytosis and heat stroke. Carbamazepine and clozapine 
should not be combined due to their risk for agranulocytosis. Valproate and other SGAPs besides 
clozapine have occasionally been associated with neutropenias due to not well-understood mechanisms. 
Rahman et al. have described neutropenia and leucopenia cases with the combination of valproate and 
quetiapine [122].     
3. Conclusion 
 This section and Table 5 provide a summary of the most important practical DI information for 
clinicians. 
3.1. Pharmacokinetic DIs and clinical implications 
Carbamazepine, phenobarbital, phenytoin and primidone are potent inducers that are likely to have 
clinically relevant effects on several SGAP levels (Table 5). Adding any of these inducers (in the absence 
of other inducers) may be associated with a decrease in SGAP serum concentration that may be associated 
with lack of efficacy. The discontinuation of these inducers (when other inducers are not prescribed) may 
be associated with an increase in SGAP serum concentration that may be associated with ADRs.  The best 
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way to control for these DIs is by checking SGAP TDM. As SGAP TDM may not be available, Table 5 
provides a best estimation of a correction factor (Figure 1) based on the limited available literature. 
The pharmacokinetic DIs associated with valproate or the mild AED inducers eslicarbazepine, 
felbamate, oxcarbazepine, rufinamide and topiramate (Table 5) are not likely to be clinically relevant in 
most patients taking SGAPs, but it cannot be ruled out that in some unusual patients they may have 
clinical relevance. In that sense, clinicians may need to be watchful when using high doses of 
oxcarbazepine (≥ 1500 mg/day) [10] or topiramate (≥ 400 mg/day) [11], particularly with highly inducible 
SGAPs such as quetiapine or lurasidone. 
3.2. Pharmacodynamic DIs and clinical implications 
As described in Section 2.3, the literature is very limited in the description of pharmacodynamic 
DIs but in our experience these types of DIs are very relevant in clinical practice (Table 5). Two 
pharmacodynamic DIs can be considered positive: i) the additive effects for mania and bipolar 
maintenance when combining valproate and SGAPs and ii) the decrease in weight that may be associated 
with combining topiramate or zonisamide with SGAPs.     
 In our experience with neurologists managing AED prescriptions and psychiatrists prescribing 
SGAPs, these specialists rarely pay enough attention to the other’s prescriptions, which may lead to high 
potential for pharmacodynamic DIs. Three additive DIs are common: increased sedation, weight gain and 
swallowing disturbances.  However, different AEDs and SGAPs have different risks for sedation or 
weight gain (Table 5). As swallowing impairment is usually a neglected ADR in published studies, there 
is no information on whether different AEDs or SGAPs have different risks for swallowing impairment. 
From the probably uncommon pharmacodynamic DIs, Table 5 highlights the potential for increased risk 
for osteoporosis and nausea for a few combinations of AEDs and SGAPs. Finally, Table 5 describes three 
potentially lethal pharmacodynamic DIs: pancreatitis, agranulocytosis/leucopenia and heat stroke. These 
ADRs are very rare and we are not sure that combinations of AEDs and SGAPs increase their risk but 
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pharmacological mechanisms suggest that it is a possibility and clinicians need to remember that in order 
to prevent or quickly diagnose these ADRs.    
4. Expert opinion 
 We have excellent understanding of the clinical relevance of DIs associated with the inductive 
properties of carbamazepine, phenytoin, phenobarbital and primidone and with the inhibitory properties of 
valproate. Unfortunately, the DI studies with SGAPs are rather limited but adding or discontinuing 
phenytoin, phenobarbital and primidone are likely to have clinically relevant effects on SGAP treatments. 
Table 5 provides correction factors based on the limited available literature.  These correction factors 
were calculated using the available pharmacokinetic studies which summarize the data, assuming that the 
average patient represents the population well; however, there is extensive pharmacokinetic variability 
between patients, and TDM measurements should be advised for optimal titration of the dosage in each 
individual. In spite of their limitations, these corrections factors are useful because: 1) many clinicians 
have no access to antipsychotic TDM and, as a matter of fact, there is limited clinical data on some SGAP 
TDM (amisulpride, aripiprazole, paliperidone, quetiapine, and ziprasidone) and very limited data on three 
compounds (asenapine, iloperidone and lurasidone); and 2) in our experience, having the correction factor 
helps clinicians to make decisions. With a correction factor of 5, quetiapine and lurasidone are poor 
SGAP choices for patients taking powerful AED inducers. The correction factors may not fully account 
for all of the possible risks of treatment because of the limited studies available; thus, there will be a need 
to periodically update these correction factors as new knowledge becomes available.  
 Eslicarbazepine, felbamate, and rufinamide are thought to be mild inducers but there are no studies 
on SGAPs to verify their limited clinical relevance. A serious limitation of the SGAP DI literature is the 
lack of studies in clinical samples with high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400 
mg/day) that would establish whether or not they induce in a clinically relevant way SGAPs dependent on 
CYP3A4 (aripiprazole, lurasidone, quetiapine and risperidone) or UGTs (asenapine and olanzapine) for 
their metabolism. As Table 5 indicates, it is very likely that AED inducers have major effects in 
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lurasidone metabolism since rifampin, another potent and widespread inducer, increased lurasidone 
metabolism by a factor of 5. Clinicians may need to be very careful with iloperidone and particularly 
asenapine. Asenapine metabolism by UGT1A4 and CYP1A2 suggests asenapine has major potential for 
being induced by carbamazepine, phenytoin, phenobarbital and primidone. There is no way of providing a 
correction factor since we are unaware of any other drug with similar metabolism to asenapine. On the 
other hand, one would like to see asenapine DI studies with repeated dosing in clinical samples, to be 
reassured that valproate effects on asenapine metabolism can be ignored by clinicians. We suspect that the 
valproate effects are small in most patients taking SGAPs but we keep surprising ourselves by finding 
unexpected valproate DIs, particularly as a possible inducer of: i) clozapine in smokers [99], or ii) 
olanzapine [106], which may be relevant in extreme conditions (valproate levels ≥ 80 μg/ml and 
olanzapine doses ≤ 10 mg/d) [107]. Paliperidone studies with strong inducers published by independent 
investigators are needed.  
It is not easy to conduct DI studies using clinically relevant doses. Pharmaceutical companies tend 
to invest in simple pharmacokinetic DI studies in volunteers frequently using single dosing to get 
approval for the marketing of their drugs, but this type of pharmacokinetic study rarely reflects clinical 
practice. DI information on package inserts is usually not designed to provide easy information to help 
clinicians to correct pharmacokinetic DIs with dose changes. The pharmacokinetic science on AED-
SGAP combinations may be in its adolescence and needing maturation, while pharmacodynamic DI 
science appears to be in its infancy.  None of the studies combining AEDs with mood stabilizers and 
SGAPs explore whether the combinations are additive or synergistic. Recent meta-analyses determined 
the effects of different monotherapies in mania, bipolar depression or maintenance but there is no 
published meta-analysis of the combinations, although most patients are treated with combinations. There 
are almost no well-controlled studies of AEDs or SGAPs in patients with aggressive behaviors or in 
adults with epilepsy and intellectual disabilities, although clinicians use AED-SGAP combinations 
frequently in them.  
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It would be naïve to simply conclude that more studies of AED-SGAP DIs are needed. They are 
obviously needed, but the lack of funding for clinical research is a major limitation. To progress in this 
area, collaboration from all interested parties is needed, including: i) drug agencies and pharmaceutical 
companies; ii) clinicians using AED-SGAP combinations; iii) researchers with expertise in a) meta-
analyses, b) pharmacoepidemiology, and c) DI pharmacology; and iv) grant agencies.   
 Drug agencies should be more insistent upon rapid approval of new SGAPs in bipolar disorder 
and require: i) thorough studies of the pharmacodynamic and pharmacokinetic DIs with carbamazepine, 
lamotrigine, lithium and valproate; and ii) clear package insert guidelines of how to better avoid or correct 
for pharmacodynamic and pharmacokinetic DIs. Carbamazepine is an anti-manic agent and probably a 
mood stabilizer, but it took too many years to get FDA approval for a bipolar disorder indication due to 
lack of interest from the pharmaceutical companies. Carbamazepine use is limited by its potential for 
toxicity, teratogenicity and DIs. If oxcarbazepine is judged to be as effective as carbamazepine in bipolar 
disorder, carbamazepine should replace oxcarbazepine. The FDA may need to think “out of the box” and 
look for new ways to encourage pharmaceutical companies possibly interested in marketing 
oxcarbazepine in bipolar disorder by providing special “deals”, assuming the companies seriously want to 
study DI issues, including the possible impact of high oxcarbazepine doses. Similarly, as several AEDs 
with chemical formulations similar to already marketed AEDs are being studied for approval for epilepsy 
(e.g., DP-valproic acid or phosphatidylcholine estric conjugate of valproic acid) the FDA and other 
agencies need to think “out of the box” about encouraging and simplifying the process of approval of 
these new AEDs for bipolar disorder.  
Clinicians frequently co-prescribe AEDs and SGAPs. Neurologists may prescribe SGAPs in their 
patients with epilepsy or other non-epileptic conditions (pain or migraine) that need treatment for 
psychosis, bipolar disorder or other SGAP off-label conditions. Psychiatrists may prescribe AEDs as 
mood stabilizers or for off-label indications in patients taking SAGPs.  Thousands of US patients take 
these combinations. There is great need of naturalistic studies describing possible additive or synergistic 
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efficacy and, more importantly, the long-term safety of these combinations. Are early sedation or early 
nausea and vomiting more frequent in some of these combinations that in the various monotherapies?  Is 
swallowing impairment or osteoporosis a long-term issue in vulnerable patients taking some of these 
combinations for years? 
Researchers with expertise in meta-analysis may need to develop better methods to study: i) safety 
of AED-SGAP combinations by comparing ADRs in available SGAP RCTs in monotherapy in 
schizophrenia versus those on adjuvant therapy in bipolar disorder, and ii)  how bipolar disorder studies 
can better compare efficacy of individual drugs versus drug combinations.  Researchers with expertise in 
pharmacoepidemiology need to explore whether rare ADRs such as risk of pancreatitis, 
agranulocytosis/leucopenia and heat stroke may be more frequently associated with AED-SGAP 
combinations than with individual drugs. Researchers with expertise in in vitro DI studies or in vivo 
clinical studies using isotopes to explore drug clearance need to better study the SGAP metabolic 
pathways and how they change when inhibitors and inducers are added, particularly in the complicated 
conditions used in clinical practices such as adding both an inducer and an inhibitor to an SGAP (e.g., 
adding carbamazepine and fluoxetine to risperidone).  
Grant and health agencies need to remember that pragmatic clinical trials are key in treating 
complex disorders such as epilepsy, schizophrenia and bipolar disorder, where polytherapy is the norm. 
Pharmaceutical RCTs do not substitute for long-term pragmatic trials that may better inform clinicians of 
the effectiveness of the various types of mono- and polytherapy frequently used in the real world of 
clinical practice. Pragmatic trials need to pay better attention to DI. 
Progress in the next few years, if this research agenda is followed, should also be accompanied by 
a better continuous medical education on DIs and improvements in neuropsychopharmacology textbooks, 
so that clinicians begin to pay more attention to pharmacodynamic and pharmacokinetic DIs associated 
with the frequent co-prescription of AEDs and SGAPs. Well-educated clinicians will help move the 
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research agenda by publishing DI case reports of unusual combinations and asking for more DI studies 
from pharmaceutical companies and researchers.  
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OTHER PHARMACOKINETIC ISSUES 
P-GLYCOPROTEIN (P-gp) 
1) P-gp plays a central role in the absorption, distribution and excretion of a wide variety of drugs.  
2) P-gp is a multidrug efflux transporter, encoded by the MDR1 gene (or ABCB1), highly expressed in 
the intestine, brain, liver and kidney.  
3) It acts as a natural defense mechanism against several drugs by limiting their absorption from the gut 
and penetration into the brain, and promoting their elimination in the bile and urine.  
4) Like metabolizing enzymes, P-gp activity can be inhibited or induced by other agents, altering the 
concentration of substrate drug in blood and brain. In particular, some antiepileptic drugs (AED) 
pharmacokinetic drug-drug interactions (DIs) currently attributed to enzyme induction may, in fact, be 
due to overexpression of such transporters resulting in the affected drug having limited gastrointestinal 
absorption or reduced penetration to the brain, or enhanced elimination in the bile and urine.  
5) Second-generation antipsychotics (SGAPs) have been reported to show various degrees of inhibitory 
effects on P-gp activity.  
6) In summary, P-gp activity is probably relevant in explaining AED and SGAP DIs but our current 
knowledge is too limited to determine P-gp’s importance. 
PROTEIN BINDING 
1) Theoretically, protein binding displacement interactions may occur between AED and SGAPs.             
2) Competition between two drugs for binding sites on plasma proteins may elevate levels of the 
displaced drug’s free fraction in plasma or tissue, thereby potentially increasing its pharmacological 
effects.    
3) However, in most circumstances this type of DI is not clinically relevant since the displaced drug is 
diluted into a large volume of distribution or is rapidly cleared, and the unbound, pharmacologically 
active concentration remains almost unchanged.  
4) In quantitative terms, displacement interactions may only be important for drugs that are highly bound 
to plasma proteins (>90%). A number of SGAPs are extensively bound to plasma proteins (Table 2), 
while among AEDs only phenytoin, valproate and tiagabine belong to this category (Table 1).  
5) Clinically relevant DIs due to increased free concentrations have occasionally been described for 
phenytoin and valproate [7], but the other AEDs or anti-inflammatory drugs usually cause increased 
valproate or phenytoin free concentrations.  
6) No clear cases of SGAPs increasing free phenytoin or valproate concentrations have been published in 
the literature.    
Figure 1. Other pharmacokinetic issues. 
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PHARMACODYNAMICS FOR ANTIEPILEPTIC EFFICACY 
ANTIEPILEPTIC ACTIVITY 
↓ Activity of voltage-dependent sodium channels 
carbamazepine,eslicarbazepine,felbamate,lacosamide,lamotrigine,oxcarbazepine,phenytoin,rufinamide,topiramate,zonisamide 
↓ Activity of voltage-dependent calcium channels 
ethosuximide, gabapentin, levetiracetam, lamotrigine, pregabalin, topiramate, zonisamide 
↑ GABA neurotransmission 
felbamate, levetiracetam, phenobarbital, primidone, stiripentol, tiagabine, topiramate, vigabatrin, valproate1 
↓ Glutamatergic neurotransmission 
felbamate, topiramate, zonisamide 
Other 
levetiracetam,2 retigabine,3 
MOOD STABILIZER ACTIVITY4 
At intracellular signaling system (inositol signaling) 
carbamazepine, valproate5 
Not well understood 
Lamotrigine 
ANXIOLYTIC ACTIVITY 
↑ GABA neurotransmission 
pregabalin6 
FOR PAIN7 
↓ Activity of voltage-dependent sodium or calcium channels 
carbamazepine, gabapentin, oxcarbazepine, pregabalin 
FOR MIGRAINE PROPHYLAXIS8 
↓ Activity of voltage-dependent sodium and calcium channels 
topiramate 
↑ GABA neurotransmission 
valproate,1 topiramate 
↓ Glutamatergic neurotransmission 
Topiramate 
WEGHT LOSS (not approved treatment)9 
Probably by inhibition of carbonic anhydrase 
topiramate, zonisamide 
Figure 2. Pharmacodynamics for antiepileptic efficacy. 
ADRs: adverse drug reactions; AED:  antiepileptic drug; RTC: randomized clinical trial.  
1There is general agreement that valproate acts mainly by increasing GABAergic neurotransmission but a 
more precise description might be that valproate has complex actions, since valproate may act at the 
voltage-dependent sodium and calcium channels [13].  
2Levetiracetam has complex actions including one that appears specific to this compound: binding to 
synaptic vesicle protein 2A interfering with the recycling of synaptic vesicles and the release of a range of 
neurotransmitters [14]. 
3Retigabine appears to open potassium channels [14]. 
4AEDs approved in the US for bipolar disorder include: i) valproate for mania; ii) carbamazepine for the 
treatment of acute manic and mixed episodes of bipolar disorder; and iii) lamotrigine for prophylaxis, 
particularly of depressive phases [15]. Treatment guidelines also consider: 1) valproate monotherapy or 
adjunctive for bipolar depression or prophylaxis, ii) carbamazepine monotherapy or adjunctive for 
prophylaxis, and iii) lamotrigine monotherapy or adjunctive for bipolar depression [15]. Gabapentin, 
lamotrigine and topiramate mania RCTs were negative [15]. Oxcarbazepine bipolar disorder RCTs appear 
promising. There are no published RCTs for eslicarbazepine, levetiracetam or zonisamide. 
40 
5Valproate is a histone deacetylase inhibitor. It is not known whether this action contributes to its mood 
stabilizing properties or not [16].   
6Pregabalin is approved for generalized anxiety disorder in Europe but not in the US. Other AEDs may 
have antianxiety properties [17]. 
7In the US approved drugs include: i) carbamazepine for trigeminal neuralgia, ii) gabapentin for 
postherpetic neuralgia, and iii) pregabalin for postherpetic neuralgia and diabetic neuropathic pain. 
Lacosamide is being studied in RCTs for diabetic neuropathic pain. Oxcarbazepine is usually considered 
an alternative for trigeminal neuralgia when patients cannot tolerate carbamazepine. Johannessen 
Landmark considers other AEDs, including levetiracetam, lamotrigine and phenytoin, as acceptable 
treatments for neuropathic pain [3]. 
8In the US, the only AEDs approved for migraine prophylaxis are topiramate and valproate.   
 9Topiramate and zonisamide treatments are frequently associated with weight loss but are not approved 
for that indication in the US. These two drugs were associated with too many ADRs in obesity RCTs [18, 
19]. 
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PHARMACODYNAMICS FOR ANTIEPILEPTIC SAFETY 
 
SEDATION 
FGAED and topiramate >2 other SGAEDs1 >2 felbamate, lacosamide, lamotrigine, tiagabine 
Possibly the same mechanism that explains antiepileptic efficacy 
COGNITIVE IMPAIRMENT 
Definitively in FGAEDs and probably in SGAEDs3 
Possibly the same mechanism that explains antiepileptic efficacy4  
BALANCE DISTURBANCES 
Most AEDS5 
Unknown/possibly the same mechanisms that explain antiepileptic efficacy 
NAUSEA AND VOMITING 
carbamazepine,eslicarbazepine,felbamate,lacosamide,lamotrigine,oxcarbazepine,phenytoin,rufinamide,topiramate,zonisamide 
Possibly ↓ activity of voltage-dependent sodium channels6 
ethosuximide, tiagabine, valproate 
Unknown 
DEPRESSION 
phenobarbital, primidone, topiramate, vigabatrin >2 zonisamide >2 felbamate, levetiracetam, tiagabine7 
Possibly ↑ GABA neurotransmission 
PSYCHOSIS (rare) 
ethosuximide, levetiracetam, lamotrigine, topiramate, tiagabine, vigabatrin, zonisamide8 
Unknown mechanisms 
AGGRESSIVE  BEHAVIOR (rare) 
gabapentin, levetiracetam, lamotrigine, phenobarbital, topiramate, vigabatrin, zonisamide9 
Unknown mechanisms  
OSTEOPOROSIS (relatively uncommon) 
carbamazepine, phenobarbital, phenytoin, primidone10 
Induction of Vitamin D metabolism 
THYROID DISTURBANCES (relatively uncommon) 
carbamazepine, phenytoin11 
Probably induction of thyroid hormone metabolism 
IDIOSYNCRATIC (very rare: 1-10/10,000-100,000) 
Stevens–Johnson syndrome/toxic epidermal necrolysis 
carbamazepine, ethosuximide, felbamate, lamotrigine, phenobarbital, phenytoin, primidone12 
Agranulocytosis and/or aplastic anemia13 
carbamazepine, ethosuximide, felbamate, phenobarbital, primidone, valproate 
Hepatitis/liver failure 
carbamazepine, felbamate, phenytoin, valproate 
Immunological and/or toxic mechanisms 
RISK FOR HEAT STROKE (very rare)14 
topiramate, zonisamide 
Inhibition of carbonic anhydrase causes sweating inhibition  
PANCREATITIS (rare)15 
valproate 
Mechanism is poorly understood 
Figure 3. Pharmacodynamics for antiepileptic safety.  
ADR:  adverse drug reaction; AED: antiepileptic drug; FGAED: first-generation antiepileptic drug; 
SGAED: second-generation antiepileptic drug.  
1All FGAEDs are definitively associated with sedation [20]. A meta-analysis found that most SGAEDs 
(gabapentin, levetiracetam, pregabalin, topiramate and zonisamide) were associated with somnolence 
when compared with placebo [20]. Other SGAEDs including oxcarbazepine, vigabatrin [20], 
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eslicarbazepine, retigabine, and rufinamide [21] also are probably associated with sedation. Felbamate, 
lacosamide, lamotrigine, and tiagabine appear to be associated with low sedation risk [20, 22]. 
2Drugs preceding ">" will produce this ADR more frequently than drugs following ">". 
3FGAEDs are associated with cognitive impairment in studies using neuropsychological testing.  There 
are few neuropsychological studies on SGAEDs. Different authors agree that phenobarbital has the worst 
cognitive profile among FGAEDs, and topiramate among SGAEDs, but disagree on the relative 
impairment associated with specific compounds and how topiramate compares with FGAEDs [23, 24]. 
Vigabatrin can be associated with visual defect fields. 
4[24]  
5FGAEDs (except for ethosuximide) are definitively associated with ataxia and other balance disturbances 
[20]. A meta-analysis indicated most SGAEDs (lamotrigine, oxcarbazepine, pregabalin, tiagabine, 
topiramate and zonisamide) are associated with balance disturbances while gabapentin and levetiracetam 
may not be [25]. Other AEDs including felbamate, vigabatrin [20], eslicarbazepine, lacosamide, 
retigabine, and rufinamide [25] are probably associated with balance disturbances. 
6Beydoun et al. proposed that nausea and vomiting may be explained by decreased activity of voltage-
dependent sodium channels [26]. Review articles focused on AED pharmacodynamics do not comment on 
possible mechanisms that may explain AED-induced nausea and vomiting. 
7Different reviews provide different frequencies of each AED-induced depression. A comprehensive 
review described frequencies >10% for phenobarbital, primidone, topiramate and vigabatrin; 7% for 
zonisamide in high doses; ≤4% for felbamate, levetiracetam and tiagabine; and <1% for the rest of the 
studied AEDs.  On the other hand, carbamazepine, lamotrigine, oxcarbazepine and valproate may have 
antidepressant properties in patients with epilepsy [27].   
8It is difficult to assess when psychosis is really an AED ADR rather than a manifestation of the 
underlying or associated illnesses. AEDs associated with psychosis include levetiracetam, lamotrigine, 
topiramate, tiagabine, vigabatrin [28], ethosuximide [29] and zonisamide [30]. Studies using lamotrigine 
and topiramate in bipolar disorder do not describe increased psychotic symptoms.  
9It is difficult to assess when aggressive behavior is really an AED ADR rather than an underlying or 
associated illness. AEDs associated with irritability or aggression are gabapentin, levetiracetam, 
lamotrigine, phenobarbital, topiramate, vigabatrin [31] and zonisamide [30]. 
10Oxcarbazepine may also be associated with osteoporosis risk. Valproate also appears to be associated 
with osteoporosis but the mechanism is not well understood.   
11Oxcarbazepine may be associated with mild thyroid disturbances.  
12Other AEDs less clearly associated with Stevens–Johnson syndrome/toxic epidermal necrolysis are 
oxcarbazepine, valproate and zonisamide. 
13Valproate is frequently associated with thrombocytopenia and more rarely, with neutropenia. Valproate-
induced thrombocytopenia appears to be dose-related and explained by direct toxic mechanism rather than 
by immunological mechanism.  
14The literature describes most cases of heat stroke associated with topiramate [32] or zonisamide [33] as 
occurring in children but adult cases during a heat wave have been described [34]. 
15The literature describes valproate-induced pancreatitis as very rare. A comprehensive review in 
Germany indicated that milder cases are much more common than the literature suggests [35]. In a review 
of all 5 years of data from a facility for 322 adults with intellectual disabilities, the frequency of 
pancreatitis in patients taking valproate was not rare; it was 7% (5/72 patients) [36]. The first author has 
similar experience that pancreatitis is not rare in these facilities. 
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PHARMACODYNAMICS FOR SGAP EFFICACY 
 
BLOCKADE OF D2 RECEPTORS AT BASAL GANGLIA AND CORTEX
1 
Explains antipsychotic efficacy in schizophrenia  
All SGAPs are approved2 
Explains antipsychotic efficacy in other psychoses  
None are approved in the US3 
Possibly explains anti-manic properties4 
aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone are approved in the US as montherapy5 
Possibly explains postulated mood-stabilizing properties (maintenance in bipolar disorder) 
aripiprazole and olanzapine are approved in the US as monotherapy6  
Possibly explains anti-irritability action in autism 
aripiprazole and risperidone are approved in the US 
Possibly explains postulated anti-OCD properties when added to serotonergic 
antidepressants7 
None are approved in the US but reasonable data exist on risperidone7,8 
DEPRESSION 
Treatment of bipolar depression 
quetiapine is approved in the US 
Adjunctive therapy of treatment-resistant depression 
aripiprazole, quetiapine, olanzapine are approved in the US9  
Mechanism of action is unknown10 
Figure 4. Pharmacodynamics of efficacy for second-generation antipsychotics  
5-HT: serotonin receptor; AP: antipsychotic; D: dopamine receptor; RCT: randomized clinical trial; 
SGAP: second-generation antipsychotic.  
1All APs are D2 antagonists except for aripiprazole which is a partial agonist (some authors have proposed 
that occasionally aripiprazole can be associated with worsening of psychosis). Brain imaging studies 
indicate that antipsychotic efficacy may be associated with D2 blockade at the basal ganglia and cortex. 
2Amisulpride is approved in Europe but has not been studied for approval in the US. 
3No SGAP is approved for psychosis (or behaviors) in dementing illness. Paliperidone is approved for 
schizoaffective disorder in the US. 
4[37] 
5Aripiprazole, asenapine, quetiapine, risperidone, and olanzapine have been approved for adjunctive 
therapy with lithium or valproate. Other SGAPs have not been studied in RCTs.  
6Quetiapine has been approved for adjunctive therapy with lithium or valproate. 
7[6] 
8[6] 
9Olanzapine is approved in combination with fluoxetine.  Risperidone had some positive results in RCTs 
[38]. 
10The mechanisms proposed in bipolar depression include: i) a high ratio between 5-HT2A/D2 receptors 
[37], and ii) a possible role for 5-HT2A or α2 blockade [39]. Common mechanisms proposed for adjunctive 
treatment in major depressive disorder include 5-HT2A blockade that may be shared by approved SGAPs 
[38]. Specific mechanism include:  i) 5-HT1A partial agonism only for aripiprazole [38]; and 5-HT2C 
antagonist and inhibition of noradrenaline transporter by norquetiapine, the main active metabolite of 
quetiapine [40]. Ziprasidone at clinical dose blocks reuptake of serotonin, noradrenaline and dopamine 
[41], which may suggest potential for antidepressant properties but the only published ziprasidone trial in 
bipolar depression indicated this compound had no more efficacy than placebo [42].   
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PHARMACODYNAMICS FOR SGAP SAFETY 
BRAIN 
EXTRAPYRAMIDAL SYMPTOMS 
amisulpride,paliperidone,risperidone>1asenapine,iloperidone,lurasidone,olanzapine,ziprasidone>1quetiapine>1clozapine2 
Blockade of D2 receptors at nigrostriatal system
2 
HYPERPROLACTINEMIA 
amisulpride,paliperidone,risperidone>1asenapine,iloperidone,lurasidone,olanzapine,ziprasidone>1quetiapine,clozapine>1 
aripiprazole3  
Blockade of D2 receptors at tubero-infundibular system
4 
WEIGHT GAIN 
clozapine, olanzapine>1 asenapine, paliperidone, quetiapine, risperidone > 
1amisulpride, aripiprazole, iloperidone, lurasidone, ziprasidone2 
Blockade of H1 (and others including 5-HT2C and M) receptors
5  
SEDATION 
clozapine >1asenapine, olanzapine >1 quetiapine >1 other SGAPs6 
Blockade of brain H1 receptors
7 
MEMORY IMPAIRMENT 
Associated with high blockade of brain muscarinic receptors in schizophrenia patients6 
Possible with clozapine 8 
↓ SEIZURE THRESHOLD  
clozapine >1 olanzapine, quetiapine >1 other SGAPs 9 
D2, H1 and α1 receptor blockade, actions at neurosteroids or by pharmacological kindling
10 
PERIPHERAL (with/without brain component) 
HYPERGLYCEMIA/HYPERLIPIDEMIA 
Secondary to weight gain (see above) 
Direct effects on glucose/lipid metabolism 
clozapine, olanzapine, quetiapine 11 
SEXUAL SIDE EFFECTS 
clozapine, risperidone, olanzapine >1 aripiprazole, quetiapine, ziprasidone12 
Hyperprolactinemia (see above) and blockade of peripheral α, M and H receptors13 
ORTHOSTATIC HYPOTENSION 
clozapine, iloperidone, risperidone, quetiapine, ziprasidone14 
Blockade of peripheral α1 receptors 
ANTICHOLINERGIC SYMPTOMS 
(Tachycardia, constipation, dry mouth, urinary retention, or blurred vision)   
15clozapine >1 olanzapine >1 quetiapine 
Blockade of peripheral muscarinic receptors 
NAUSEA 
aripiprazole, lurasidone, ziprasidone 
Unknown16 
PROLONGATION OF QTC 
iloperidone, ziprasidone >1 amisulpride, asenapine, clozapine, lurasidone, quetiapine, risperidone, olanzapine >1 
aripiprazole17 
Blockade of heart potassium repolarizing channels 
AGRANULOCYTOSIS 
clozapine (<1%) 
Probably immunological 
NEUTROPENIA (very rare) 
Possibly ALL 
Unknown 
RISK FOR HEAT STROKE (very rare) 
Most published cases also involve FGAPs18 
Dopaminergic blockade interferes with temperature regulation 
Muscarinic blockade from antiparkinsonian or from AP (see anticholinergic) inhibits sweating 
Figure 5. Pharmacodynamics of safety for second-generation antipsychotics 
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5-HT: serotonin receptor; ADR:  adverse drug reaction; AP: antipsychotic; D: dopamine receptor; FGAP: 
first-generation antipsychotic; H: histamine receptor; M: muscarinic receptor; SGAP: second-generation 
antipsychotic.  
1Drugs preceding ">" will produce this ADR more frequently than drugs following ">". 
2Data from a comprehensive review [43] supplemented with data on asenapine [44], iloperidone [45] and 
lurasidone [46].  
3Data from a comprehensive review [43] supplemented with data on asenapine [44], iloperidone [47] and 
lurasidone [46].  
4All APs are D2 antagonists except for aripiprazole, a partial agonist. The lower propensity of SGAPs 
other than aripiprazole to cause extrapyramidal symptoms is explained by two theories: i) a high ratio 
between 5-HT2A/D2 receptors, and ii) low affinity and fast dissociation from D2 (only clozapine and 
quetiapine will be “atypical” since they are displaced by endogenous dopamine) [48].  
5Studies relating weight gain within different APs and receptor affinity indicate that H1 affinity is the best 
predictor of weight gain. Some animal studies indicate that H1 blockade of other receptors (particularly 5-
HT2C and muscarinic) may be needed to produce hyperphagia in animal studies [48].  
6Data from a comprehensive review [49] supplemented with data on asenapine [44] and iloperidone [45].   
7H1 antagonism is probably the major contributing mechanism to sedation but other receptor blockade 
may also contribute.  Aripiprazole and ziprasidone have also been associated with early insomnia and 
activation [50]. It is unknown whether these compounds’ pharmacodynamic differences or individual 
susceptibility explain this activation.  
8Blockade of M1 and M2 receptors has been associated with impaired learning and memory in animal 
studies [51]. It is difficult to detect cognitive impairment in the context of schizophrenia but high 
antimuscarinic activity was associated with worse memory functioning in an AP meta-analysis.  
Clozapine had a worse profile than risperidone and olanzapine [52].  Clozapine has definitively high 
antimuscarinic activity. Olanzapine and high doses of quetiapine may also be associated with clinically 
relevant antimuscarinic activity [52]. Thus, olanzapine and high doses of quetiapine may occasionally be 
associated with memory impairment. 
9A comprehensive review [53] provided no comparative data on amisulpride, asenapine, iloperidone, or 
lurasidone. 
10[54]. 
11Other SGAPs may not have direct effects on glucose or lipid metabolism, but this has not been 
completely established.  
12A meta-analysis provided no comparative data on amisulrpide, asenapine, iloperidone, or lurasidone 
[55].  
13[55]. Priapism is rare but is the most severe sexual ADR and is probably explained by α1 (and possible 
α2) receptor blockade [48].  
14Clozapine, iloperidone, risperidone, quetiapine, and ziprasidone need dose titration to avoid orthostatic 
hypotension. Orthostatic changes are not seen after intramuscular injections of ziprasidone, so ziprasidone 
probably has low risk of orthostatic hypotension. Other SGAPs with lower risk for orthostatic 
hypotension are olanzapine (particularly in intramuscular preparation) and asenapine. 
15Clozapine causes hypersalivation. It is believed that clozapine may be a partial agonist at M1 and M3 
receptors. Norclozapine, clozapine’s main metabolite, is definitively an allosteric agonist of M1 [51]. 
16Antipsychotics, because of their dopaminergic blockade, are considered anti-emetic drugs, so it is not 
known what mechanism explains the association of these three drugs with nausea in the first one or two 
weeks of treatment. Other SGAPs may also occasionally be associated with nausea.       
17Data from a comprehensive review [43] supplemented with data on amisulpride [56], asenapine [44], 
iloperidone [57] and lurasidone [58].  
18Most published cases including SGAPs also had FGAPs co-prescribed [59]. 
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Table 1. Pharmacokinetic parameters of antiepileptics. 
 Bioavail
-ability 
(%) 
Protein 
binding 
(%) 
Half-
life (h) 
Most 
important 
way of 
elimination1 
Other ways of elimination Active metabolites Non-linear kinetics 
FIRST GENERATION  
Carbamazepine 75-85 75 5-26 CYP3A42 CYP2C8, CYP1A2, UGT2B7 Carbamazepine 
epoxide7 
Non-linear until 
induction is stable 
Ethosuximide 90-100 <10 25-70 CYP3A42 CYP2E1, renal   
Phenytoin 90 90 7-80 CYP2C92 CYP2C19 (less important: 
CYP2C18, CYP3A4) 
 Non-linear6 
Phenobarbital >95 45-60 70-130 CYP2C92 CYP2C19,  CYP2E1,  
N-glucosidation, renal  
 Non-linear until 
induction is stable 
Primidone >90 10 5-20 CYP2C92 Renal, CYP2C19,  CYP2E1,        
N-glucosidation, 
Phenobarbital Non-linear until 
induction is stable 
Valproate >90 70-95 8-16 Several 
UGTs 
-oxidation, CYP 2C9 (other 
CYPs are minor)  
 Non-linear for total 
concentration6 
SECOND GENERATION 
Eslicarbazepine 100 30 13-20 UGTs3 Renal S-licarbazepine  
Felbamate 90 20-25 11-25 CYP3A42 Renal, CYP2E1, UGTs    
Gabapentin <65 0 5-9 Renal   Non-linear6 
Lacosamide 100 <15 12-16 CYP2C192 Renal   
Lamotrigine >95 55 25 UGT1A42    
Levetiracetam  100 <10 6-8 Renal  Esterase hydrolysis in blood   
Oxcarbazepine  100 40 7-12 Renal UGTs MHD (monohydroxy 
derivate) 5  
 
Pregabalin >90 0 5-7 Renal    
Retigabine 60 80 8-10 Acetylation UGTs   
Rufinamide 85 30 8-12 Carboxyles-
terases 
   
Stiripentol >70 99 4.5-13  CYP1A2, CYP2C19, CYP3A4, 
UGTs4 
  
Tiagabine 100 96 5-9 CYP3A42    
Topiramate 100 13-17 10-30 Renal CYP    
Vigabatrin >50 0 4-7 Renal    
Zonisamide 100 50 50-70 CYP3A42 N-acetylation transferase, renal   
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CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyl transferase 
1This refers to normal metabolism. Lack of polymorphic enzymes, as well as major inhibition or induction, can change the major way of eliminating the drug 
from the body.  In some CYPs (e.g., CYP2C19) some patients do not have active enzymes; they are called poor metabolizers (PMs).  Others may have too much 
enzyme; they are called ultrarapid metabolizers (UMs).  If a drug is metabolized by a CYP associated with PMs or UMs, these subjects metabolize the drug in a 
different way than average subjects. Adding a potent inhibitor that completely inhibits an enzyme causes a PM “phenocopy” as long the inhibitor effects are 
present; adding an inducer causes a UM phenocopy as long the inducer effects are present. 
2Any substrate competes with others for the corresponding enzyme and inhibits it; the potency of the inhibition is influenced by substrate affinity and dose. In 
most clinical situations competitive inhibition is probably irrelevant. In unusual polypharmacy situations, adding a competitive inhibitor (such as AEDs, which 
are not normally considered inhibitors) in a patient taking a drug with a narrow therapeutic window may affect another drug’s drug metabolism due to inhibitor 
accumulation past the tipping point. 
3Eslicarbazepine is a pro-drug that is activated by hepatic esterases to S-licarbazepine. S-licarbazepine is eliminated by UGTs and by the kidney (unchanged).  
4There are four metabolic pathways. No specific enzyme can be considered as the most important enzyme.  
5MHD is also called licarbazepine. Oxcarbazepine is a pro-drug and is activated by a cytosolic arylketone reductase that converts it to MHD, the active drug.  
6Metabolic saturation explains phenytoin non-linear kinetics. Protein binding saturation explains valproate non-linear kinetics for total serum concentrations. 
Absorption saturation explains gabapentin and rufinamide  nonlinear kinetics. 
7Carbamazepine epoxide is metabolized by an epoxide hydroxylase.
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Table 2. Pharmacokinetic parameters of second-generation antipsychotics.  
 
 Bioavailability 
(%) 
Protein 
binding (%) 
Half-life 
(h) 
Most important way of 
elimination1 
Other ways of elimination Active metabolites 
Amisulpride 43-48 17 12 Renal Biliary  
Aripiprazole 87 99 48-68 CYP2D62 CYP3A4 Dehydro-aripiprazole 
Asenapine 353 95 1-2 UGT 1A42 CYP1A2, CYP2D6, CYP3A4  
Clozapine 12-81 95 6-33 CYP1A22 CYP2C19, CYP3A4, CYP2D6 Norclozapine5 
Iloperidone 96 93 20-24 CYP2D62 CYP3A4,  CYP1A2, CYP2E1 P88,6 P95 
Lurasidone 9-194 99 18 CYP3A42   ID-14823 
Olanzapine 60-80 93 20-70 CYP1A22 CYP2D6, UGT1A4, FMO  
Paliperidone 28 30 24 Renal UGT, CYP2D6, CYP3A4  
Quetiapine NA 83 5-8 CYP3A42 CYP2D6 Norquetiapine 
Risperidone 68 90 3-24 CYP2D62 CYP3A4, renal 9-hydroxy-risperidone 
Ziprasidone 604 99 4-10 Aldehyde oxidase CYP3A4  
CYP: cytochrome P450; NA: not available; UGT: uridine diphosphate glucuronosyl transferase  
1This refers to normal metabolism. Lack of polymorphic enzyme, as well as major inhibition or induction, can change the major way of eliminating the drug from 
the body. In some CYPs (e.g., CYP2D6 and CYP2C19) some patients do not have active enzymes, they are called poor metabolizers (PMs).  Others may have too 
much enzyme; they are called ultrarapid metabolizers (UMs).  If a drug is metabolized by a CYP associated with PMs or UMs, these subjects metabolize the drug 
in a different way than average subjects. Adding a potent inhibitor that completely inhibits an enzyme causes a PM “phenocopy” as long the inhibitor effects are 
present; adding an inducer causes a UM phenocopy as long the inducer effects are present. When patients are taking major inducers (carbamazepine, 
phenobarbital, phenytoin or primidone), CYP3A4 may became the most important enzyme eliminating aripiprazole or risperidone.  
2Any substrate competes with others for the corresponding enzyme and inhibits it; the potency of the inhibition is influenced by substrate affinity and dose. In 
most clinical situations competitive inhibition is probably irrelevant. In unusual polypharmacy situations, adding a competitive inhibitor (such as SGAPs which 
are not normally considered inhibitors) in a patient taking a drug with a narrow therapeutic window may affect another drug’s drug metabolism due to inhibitor 
accumulation past the tipping point. 
3Asenapine is administered sublingually; drinking or eating < 10 minutes after administration may decrease absorption.  
4Decreased absorption when not administered with food. 
5Norclozapine does not appear to have antipsychotic efficacy but it may contribute to anticholinergic effects and hypersalivation. 
6It does not cross the blood-brain barrier. It may contribute to peripheral adverse drug reactions. 
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Table 3. Effects of antiepileptic drugs on the most common drug-metabolizing enzyme systems. 
Antiepileptic Induction Enzymes Inhibition Enzymes 
First-Generation Antiepileptics 
Carbamazepine Yes CYP1A2, CYP2A6, 
CYP2B6, CYP2C9, 
CYP2C19, CYP3A4, 
UGT1A1, UGT2B7, 
UGT2B15,  
Epoxide hydrolase 
None1 N/A 
Ethosuximide None2 N/A None1 N/A 
Phenobarbital, 
Primidone 
Yes CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, 
CYP2C19, CYP2E1, 
CYP3A4, UGT, Epoxide 
hydrolase 
None1 N/A 
Phenytoin 
 
 
Yes CYP1A2, CYP2B6, 
CYP2C8, CYP2C9,  
CYP2C19, CYP3A4, 
UGTs, Epoxide hydrolase 
None1 N/A 
Valproic Acid Unclear  Yes CYP2C9, UGT1A4, 
UGT2B7, Epoxide 
hydrolase, N-
glucosidation 
Second-Generation Antiepileptics 
Eslicarbazepine Weak CYP3A4 Yes CYP2C19 
Felbamate Weak CYP3A4 Yes CYP2C19, -oxidation 
Gabapentin None2 N/A None N/A 
Lacosamide None2 N/A None1 N/A 
Lamotrigine Weak UGT None1 N/A 
Levetiracetam None2 N/A None N/A 
Oxcarbazepine Weak CYP3A4, UGTs Weak CYP2C19 
Pregabalin None2 N/A None N/A 
Retigabine None2 N/A None N/A 
Rufinamide Weak CYP3A4, UGTs Weak CYP2E1 
Stiripentol None2 N/A Yes CYP1A2, CYP2C19, 
CYP2D6, CYP3A4 
Tiagabine None2 N/A None1 N/A 
Topiramate Weak CYP3A4, -oxidation Weak CYP2C19 
Vigabatrin None2 N/A None N/A 
Zonisamide  None2 N/A None1 N/A 
CYP: cytochrome P450; N/A: not applicable; UGT: uridine diphosphate glucuronosyl transferase  
1None means that the antiepileptic is not a clinically relevant inhibitor. Antiepileptic drugs, as any substrate 
(see Table 1), can behave as a competitive inhibitor and in rare circumstances this inhibition may have 
clinical relevance. 
2None means that the antiepileptic is not a clinically relevant inducer.
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Table 4. Summary of pharmacokinetic drug interactions between antiepileptics and second-generation antipsychotics.  
Antiepileptic Antipsychotic Effect Proposed mechanism 
Carbamazepine Aripiprazole Mean AUC decrease by 71% and 4-fold increase in clearance CYP3A4 induction 
Clozapine Decrease in plasma clozapine concentrations by 50% CYP1A2 and CYP3A4 
induction  
Olanzapine Decrease in olanzapine dose-normalized concentrations by 36-71% CYP1A2 and UGT induction 
Paliperidone Decrease in steady-state Cmax and AUC of paliperidone by 37%  Renal P-gp induction 
Quetiapine Decrease of quetiapine peak plasma concentration (Cmax) by 80%, 
AUC by 87% and a 7.5-fold increase of its oral clearance  
CYP3A4 induction 
Risperidone Decrease in risperidone total active moiety concentrations by 50% CYP3A4 induction 
Ziprasidone  Decrease in ziprasidone AUC by 36%  CYP3A4 induction 
Lamotrigine Clozapine No significant changes in plasma clozapine concentrations  
Olanzapine Moderate elevation of plasma olanzapine concentrations by 15% UGT1A4 competitive inhibition 
Quetiapine Moderate decrease of plasma quetiapine concentrations by 17%  
Risperidone No significant changes in plasma risperidone concentrations  
Oxcarbazepine Clozapine 
Olanzapine 
Risperidone 
No significant changes in plasma concentrations of antipsychotics  
Phenobarbital Clozapine Decrease in plasma clozapine concentrations by 35% CYP1A2, CYP3A4 and UGT 
induction 
Phenytoin Quetiapine Decrease by 80% of plasma quetiapine concentrations and 5-fold 
increase of its clearance 
CYP3A4 induction  
Topiramate Clozapine 
Olanzapine 
Quetiapine 
Risperidone 
No significant changes in plasma concentrations of antipsychotics  
Valproic acid Aripiprazole Decrease in plasma aripiprazole concentrations by 24% CYP3A4 and/or gastrointestinal  
P-gp induction 
Clozapine Variable results reported with plasma clozapine concentrations 
slightly increased, slightly decreased or unchanged 
 
Olanzapine Decrease in plasma olanzapine concentrations by 18-50% CYPs and/or UGT induction  
Quetiapine No significant changes in plasma quetiapine concentrations  
Risperidone No significant changes in plasma risperidone concentrations  
AUC: area under the curve; CYP: cytochrome P450; P-gp: P-glycoprotein; UGT: uridine diphosphate glucuronosyl transferase. 
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Table 5. Practical summary of antiepileptic and second-generation antipsychotic drug interactions       
ANTIEPILEPTICS  SGAPs OUTCOME ACTIONS
PK DI. Powerful inducers:     
carbamazepine, phenobarbital 
phenytoin, primidone 
A.↓level 2-4 wks after adding inducer 
    ↑level 2-4 wks after D/C inducer 
A. In absence of TDM use correction factor:   
quetiapine, lurasidone?>1 52 
olanzapine, clozapine 2>1 2-4 
aripiprazole,iloperidone, risperidone>1 2  
asenapine? >1 Unknown 
amisulpride, paliperidone, ziprasidone Not relevant Possibly no clinically relevant changes 
PK DI. Mild inducers:3  
eslicarbazepine, felbamate,  
oxcarbazepine,4 topiramate,4  
rufinamide 
quetiapine, lurasidone?>1 ↓mild level 2-4 wks after adding inducer 
↑mild level 2-4 wks after D/C inducer 
 
A. Monitor for ↓ efficacy after adding inducer 
B. Monitor for ADRs after discontinuing inducer olanzapine, clozapine 2>1 
aripiprazole,iloperidone,risperidone>1 
asenapine? >1 
PK DI. valproate olanzapine,  ↓ mild level A. Be aware 
     Can’t rule out occasional clinical relevance clozapine 2 mild ↓ or ↑ level 
PD DI. valproate SGAP ↑ efficacy in mania/maintenance5 A. Be aware 
B. Monitor for ADRs 
PD DI.  
FGAEDs, topiramate >1 
Other  
clozapine, asenapine,olanzepine> Additive sedation risk 
 
A. Monitor for sedation 
 quetiapine> 
Other 
Absence of PD DI. 
felbamate, lacosamide, 
lamotrigine, tiagabine 
aripiprazole, ziprasidone These AEDs and SGAPs may not be 
sedating 
Be aware 
PD DI.  
carbamazepine, gabapentin  
pregabalin, valproate 
clozapine, olanzapine >1 Additive weight gain risk  A. Monitor weight 
B. Monitor serum glucose and lipids6 asenapine, paliperidone, quetiapine, 
risperidone>1  
amisulpride, aripiprazole, iloperidone, 
lurasidone, ziprasidone 
PD DI.  
topiramate, zonisamide7 
SGAPs Weight loss Be aware 
PD DI. AEDs SGAPs  Additive impaired swallowing risk8 Monitor closely in patients with intellectual 
disability or dementia 
PD DI.  carbamazepine, 
phenobarbital, phenytoin, 
primidone >1  
oxacarbazepine, valproate 
amisulpride, paliperidone, risperidone Possible additive osteoporosis risk Monitor closely  
PD DI. valproate rarely9 SGAPs more rarely10 Possible additive pancreatitis risk  A. Be vigilant (can be lethal) 
PD DI.   
carbamazepine very rarely clozapine rarely 
 
Both have risk for agranulocytosis 
 
DO NOT COMBINE 
PD DI. valproate rarely SGAPs rarely Both associated with leucopenia  A. Be vigilant (can be lethal)  
PD DI.  
topiramate, zonisamide rarely 
SGAPs rarely ↑ risk with 
anticholinergic drugs11 
Both associated with heat stroke  In elderly and/or exposed to strenuous exercise/ 
high temperatures:  
A. Be vigilant (can be lethal): 
52 
B. Encourage proper hydration.    
ADR: adverse drug reaction; AED: antiepileptic drug; FGAED: first-generation antiepileptic drug; PD DI: pharmacodynamic drug interaction; 
PK DI: pharmacokinetic drug interaction; SGAP: second-generation antipsychotic; SGAED: second-generation antiepileptic drug; ?: reflects 
that information on asenapine and lurasidone is limited. It is likely that asenapine may be influenced by potent inducers but it has not been 
studied.   
1Drugs preceding ">" will produce a more powerful outcome than the drugs listed on the following line. 
2Please be aware that a correction factor of 5 was suggested by a phenytoin pharmacokinetic study by Wong et al. [80], but a correction factor 
of 7.5 was suggested by a carbamazepine pharmacokinetic study [56]. Rifampin, a CYP3A4 inducer, increased lurasidone metabolism by a 
factor of 5.   
3The risk of SGAP-induction reflects what we know from powerful AED inducers. 
3High doses of oxcarbazepine (≥ 1500 mg/d) or TMP (≥ 200 mg/d).  
5The combination of valproate with SGAPs may be more effective than monotherapy. This is particularly well established in mania; this type of 
combination for bipolar maintenance is standard clinical practice. As far as we know, there is no such data for additive effects for the 
combination of carbamazepine with SGAPs but this combination is frequently recommended for maintenance by pharmacological guidelines. 
Any study trying to establish the additive effects of carbamazepine and SGAPs in bipolar disorder will need to correct for pharmacokinetic DIs. 
6Serum glucose and lipid abnormalities may be associated with weight gain. Drugs can also produce direct effects on glucose and/or lipid 
metabolism. Clozapine, olanzapine and quetiapine have been definitively associated with hyperglycemia and hyperlipidemia independent of 
weight gain. Carbamazepine has been associated with increases in total cholesterol and high density lipoprotein (HDL) cholesterol. Some 
studies have associated phenytoin with hyperglycemia and increases in total cholesterol. Valproate has been associated with lower total 
cholesterol, which may be positive, but is also associated with lowering HDL and insulin resistance.  
7Felbamate is associated with weight loss but it cannot be used for that indication due to its high risk for severe ADRs. 
8Although it has not been studied: i) all SGAPs can interfere with swallowing and cause esophageal dysmotility, ii) AEDs can also interfere 
with swallowing, and iii) additive or synergistic pharmacodynamic DIs upon swallowing are likely. 
9Valproate is definitively associated with pancreatitis but the mechanism is not known.  
10Rarely, SGAPs have been associated with pancreatitis, but the connection is not completely established. Some of these cases of pancreatitis 
were associated with hypertriglyceridemia, which is a known risk factor for pancreatitis. Clozapine, olanzapine and quetiapine have been 
definitively associated with hyperlipidemias that can occur in the absence of obesity and are probably explained by the direct effects of the 
drugs on lipid metabolism. 
11Clozapine, olanzapine and high doses of quetiapine have anticholinergic (antimuscarinic) activity. Antiparkinsonian drugs can be co-
prescribed with SGAPs and have high anticholinergic (antimuscarinic) activity. 
 
